Search results for "From ACP Journal Club"
Semaglutide reduced a composite of CV events at two years in patients with type 2 diabetes and high CV risk
Semaglutide, a new once-weekly glucagon-like peptide-1 (GLP-1) analogue, reduced cardiovascular (CV) events compared to placebo, according to a manufacturer-sponsored study.
https://diabetes.acponline.org/archives/2017/02/10/7.htm
10 Feb 2017
In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding
Although an industry-funded trial found little net benefit overall from adding ticagrelor to aspirin, it's possible that some patients with higher ischemic risk and low bleeding risk could benefit, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/02/14/6.htm
14 Feb 2020
In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis
Taking canagliflozin, at a dose of either 100 mg or 300 mg per day, was associated with risk of diabetic ketoacidosis, according to a trial that randomized patients with type 1 diabetes to either of the doses or a placebo.
https://diabetes.acponline.org/archives/2016/08/12/5.htm
12 Aug 2016
In screen-detected type 2 diabetes, intensive therapy did not differ from usual care for CV events at 10 years
Despite the lack of observed benefit in this analysis, primary care physicians should continue to operate under the reasonable assumption that addressing cardiovascular (CV) risk factors improves longevity, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/05/08/6.htm
8 May 2020
Bariatric surgery improved HbA1c more than intensive medical therapy in obese patients with uncontrolled type 2 DM
Longer-term outcomes show that adding Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy to intensive medical therapy enabled more obese, type 2 diabetes patients to maintain glycemic control.
https://diabetes.acponline.org/archives/2014/09/12/6.htm
12 Sep 2014
In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y
A subanalysis of a trial of empagliflozin for patients with cardiovascular disease (CVD) found lower rates of nephropathy in those randomized to empagliflozin rather than placebo.
https://diabetes.acponline.org/archives/2016/11/11/7.htm
11 Nov 2016
In type 2 diabetes treated with high-dose insulin, liraglutide reduced HbA1c
The hypoglycemia rate was higher in the first month after initiation of liraglutide, but the overall hypoglycemia rate over the 6-month follow-up was similar in liraglutide and placebo patients.
https://diabetes.acponline.org/archives/2016/11/11/5.htm
11 Nov 2016
In type 2 diabetes, early metformin plus vildagliptin reduced treatment failure vs a stepwise approach
Despite this study's findings, clinicians should continue to follow guidelines and use metformin as the first-line drug intervention, then select from other drug classes when there is a compelling indication, advised an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/03/13/7.htm
13 Mar 2020
Self-monitoring of blood glucose did not improve HbA1c or QOL at 1 year in non-insulin-treated type 2 diabetes
The randomized controlled trial adds to the evidence about routine use of self-monitoring of blood glucose for all patients with type 2 diabetes, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2017/11/10/7.htm
10 Nov 2017
In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide
This industry-funded trial of tirzepatide, a unimolecular dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, heralds a new era of “twincretins” in diabetes management, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/11/12/6.htm
12 Nov 2021